Multiple myeloma - bortezomib: review decision - November 2012 information
History
A list of downloadable documents created during development.
Background information
-
-
-
Multiple myeloma - bortezomib: review proposal - March 2012 information
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 148 KB)
-
TA129 Multiple myeloma - bortezomib: review update - November 2011 information
-
TA129 Multiple myeloma - bortezomib: review update - January 2011 information
-
Bortezomib monotherapy for relapsed multiple myeloma (final appraisal determination)
-
Bortezomib monotherapy for relapsed multiple myeloma (final appraisal determination)
-
Bortezomib monotherapy for relapsed multiple myeloma (final appraisal determination) information
-
Bortezomib monotherapy for relapsed multiple myeloma (final appraisal determination) (PDF 1.23 MB)
-
-
Consultee and commentator comments on the ACD
-
Manufacturer/sponsor submission from Janssen-Cilag (PDF 345 KB)
-
Cancer Network Pharmacists Forum and British Oncology Pharmacy (joint comments) (PDF 191 KB)
-
-
-
-
UK Myeloma Forum, the British Society for Haematology and the RC of Pathologists (PDF 77 KB)
-
-
-
-
Supporting letter confirming the Velcade response scheme - Department of Health (PDF 21 KB)
-
Supporting letter confirming the Velcade response scheme - Janssen Cilag (PDF 34 KB)
-
Supporting letter confirming the Velcade response scheme - WAG (PDF 26 KB)
Multiple myeloma - bortezomib: appraisal consultation
-
Multiple myeloma - bortezomib: appraisal consultation
-
Multiple myeloma - bortezomib: appraisal consultation document information
-
Multiple myeloma - bortezomib: evaluation report
-
Additional analysis (post-appeal) from Ortho Biotech (PDF 184 KB)
-
Department of Health response to responder scheme (PDF 16 KB)
-
Department of Health summary of responder scheme (PDF 17 KB)
-
Welsh Assembly Government response to responder scheme (PDF 35 KB)
-
-
-
-
-
Incremental and Pairwise analysis (prepared by Technical Lead and Technical Adviser) (PDF 93 KB)
-
Additional expert statements detailing response to the request made by the Appeal Panel in terms of the three scenarios outlined in the Appeal Panel Decision
-
-
-
-
-
Letter sent to consultees and commentators updating them on the status of the appraisal
Letter to Department of Health following Appeal Panel decision
Letter to consultees and commentators requesting views on unlicensed use
Letter to Janssen-Cilag (Ortho Biotech) following Appeal Panel decision requesting additional cost effectiveness evidence
Letter to Welsh Assembly Government following Appeal Panel decision
Multiple myeloma - bortezomib: Appeal panel decision
Appeal by Janssen-Cilag Ltd
Joint appeal by the Royal College of Pathologists and the British Society for Haematology
Covering letter for joint appeal by Myeloma UK, Cancerbackup and Leukaemia CARE
Joint appeal by Myeloma UK, Cancerbackup and Leukaemia CARE
Letter to John Redwood referenced in Myeloma UK joint submission
Appeal by UK Myeloma Forum
Appeal against bortezomib monotherapy for relapsed multiple myeloma
Final appraisal determination
-
Final appraisal determination: Bortezomib monotherapy for relapsed multiple myeloma information
-
-
Response to consultee and commentator comments on the ACD (PDF 347 KB)
-
Response to patient carer organisations public and web comments on the ACD (PDF 26 KB)
-
Response to professional organisation's public and web comments on the ACD (PDF 55 KB)
-
Consultee and commentator comments on the ACD
-
-
Department of Health, Social Services and Public Safety - Northern Ireland (PDF 45 KB)
-
-
Leukemia Research, International Myeloma Foundation (UK) and Leukaemia Care (PDF 18 KB)
-
-
-
-
-
-
-
Expert statements
-
-
-